Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.
Smaller companies like Intercept Pharmaceuticals Inc. and Genfit SA are further ahead in the race to bring the first therapy to market in non-alcoholic steatohepatitis (NASH), but Pfizer Inc. and Novartis AG will study their NASH candidates in combination trials in an effort to win what one executive describes as a marathon, rather than a sprint.
The pharma giants announced a partnership Oct. 29 to study Novartis’ Phase II farnesoid X receptor (FXR) agonist tropifexor (LJN452)...
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
